Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC: SDZNY) (OTC: SDZXF), and Aurobindo Pharma, are resisting a bid by several states to transfer antitrust lawsuits out of the Eastern District of Pennsylvania, cautioning against potential "chaos" and duplicity in litigating identical price-fixing claims across multiple venues.
大型製藥公司，包括梯瓦製藥工業有限公司（紐約證券交易所代碼：TEVA）、山德士集團（場外交易代碼：SDZNY）（場外交易代碼：SDZXF）和奧羅賓多製藥公司，都在抵制多個州提出的將反壟斷訴訟移出賓夕法尼亞東區的提議，並警告說，在多個場所提起相同的定價索賠時可能出現 “混亂” 和重複性。
The companies filed a motion urging the U.S. Judicial Panel on Multidistrict Litigation to maintain the consolidation of the lawsuits in Pennsylvania federal court, opposing the states' initiative to move their cases back to federal court in Connecticut, where the litigation originated in 2016, Reuters noted.
路透社指出，兩家公司提出了一項動議，敦促美國多地區訴訟司法小組繼續合併賓夕法尼亞州聯邦法院的訴訟，反對該州將案件移回康涅狄格州聯邦法院的倡議，該訴訟起源於2016年。
The extensive litigation encompasses allegations against dozens of generic pharmaceutical companies for conspiring to fix prices on hundreds of drugs.
這起廣泛的訴訟包括對數十家仿製藥公司的指控，這些公司密謀固定數百種藥品的價格。
At the center of the dispute over venue lies a new federal law empowering states to select their preferred jurisdictions for pursuing antitrust cases.
關於地點的爭議的核心是一項新的聯邦法律，該法律授權各州選擇首選司法管轄區來追查反壟斷案件。
This legal development, known as the Venue Act, has already influenced decisions in unrelated cases, notably one involving Google, wherein a U.S. appeals court allowed a state to exit multidistrict litigation in Manhattan federal court.
這一被稱爲《訴訟地法》的法律發展已經影響了無關案件的裁決，尤其是涉及谷歌的案件，在該案中，美國上訴法院允許一個州退出曼哈頓聯邦法院的多地區訴訟。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明： 該內容部分是在人工智能工具的幫助下製作的，並由Benzinga編輯審閱和發佈。
譯文內容由第三人軟體翻譯。